Patient examples
Treating symptoms of diabetic gastroparesis and refractory GERD with Metozolv ODT may be effective for some people.1 Here are a few examples of how Metozolv ODT can help with your treatment.
A breeze on the go
“It seemed like I’d tried a different GERD therapy for every city I’ve visited. After numerous treatment plans failed to help, I made it a priority to talk to my healthcare professional about a different treatment approach. He diagnosed me with refractory GERD and recommended I try Metozolv ODT. Because it’s an orally disintegrating tablet,1 it fits into my hectic travel routine. I can take it anywhere, without liquid: on a plane, a train, in a cab—even on an elevator.”
— Kyle, 34*
A judicial review
“I was constantly forgetting to have a bottle of water with me on the bench so I could take my metoclopramide tablets 30 minutes before each meal. I was complaining about how I felt after lunch one day when my daughter handed down a verdict for my diabetic gastroparesis symptoms. She’s a nurse, and she recommended that I talk to my healthcare professional about Metozolv ODT. I sure am glad I did. Metozolv ODT is a convenient form of metoclopramide that rapidly† melts on the tongue, so I can take it anywhere, without liquid. It allows me to take my metoclopramide as prescribed. Yesterday, I even took it during a trial, just before treating my daughter to a quick lunch.”
— Gloria, 54*
Treatment is served
“After a long shift of cooking for other people, I love to treat myself to a meal prepared by somebody else! But it was hard to enjoy dinner when my diabetic gastroparesis symptoms stopped me from finishing the main course. That’s why I talked to my healthcare professional about Metozolv ODT, an orally disintegrating tablet1 that controls the nausea and bloating I used to feel immediately after eating. Luckily for me, it works on my symptoms. Now, I’m ready to try the chicken tetrazzini at the new restaurant down the street.”
— Sal, 47*
Is Metozolv ODT right for you?
Discover valuable tools and resources about diabetic gastroparesis, refractory GERD, and Metozolv ODT
Learn more about Metozolv ODT
*Not an actual patient. Individual results may vary.
†Metozolv ODT disintegrates on the tongue in a median of 53.5 seconds (mean ± standard deviation, 76.8 ± 110.6 seconds).1
Reference: 1. METOZOLV ODT [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2009.
IMPORTANT SAFETY INFORMATION
Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive
dyskinesia increases with the duration of treatment and the total cumulative dose.
Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive
dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.
Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh
the risk of developing tardive dyskinesia.
METOZOLV™ ODT (metoclopramide HCl) is indicated as short-term therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD)
who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric
stasis) in adults. Therapy should not exceed 12 weeks in duration. METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage,
or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal
reactions. METOZOLV ODT should be used with caution in patients showing acute dystonic reactions, drug-induced Parkinsonism, or other extrapyramidal symptoms;
neuroleptic malignant syndrome; with a prior history of depression; hypertension; congestive heart failure and ventricular arrhythmia. Patients may experience
withdrawal symptoms after stopping the use of METOZOLV ODT.
In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.
Please see accompanying full Prescribing Information
for Metozolv ODT, including BOXED WARNING.